Please discuss how the applied concentrations are related to the clinically used dosage (75 mg administered orally twice https://clinicaltrials.gov/ct2/show/NCT02448290) and why not the more efficient MEK1 inhibitor trametinib was used for the experiments.
The authors argue that MACC1 expression did not significantly influenced cell proliferation in the two cell line models.